tiprankstipranks
Top Stocks
U.S. Stock Market OverviewTop Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
Top ETFs by AUMSPY ETFQQQ ETF
Stock Comparison
Energy StocksOil StocksBest Value StocksAirline StocksElectric Vehicle StocksMATANA Stocks
New
Bank StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
Global Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsPre-Market BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsTools for Trading PlatformsData for Hedge FundsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Top ETFs by AUM
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
U.S. Markets
Market Movers
Expert Center
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
Top ETFs by AUM
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Energy Stocks
EV Stocks
Crypto News
Dividend Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Pre-Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

Corona

Novavax: Street Underestimating Anticipated Strong Q2 and Outlook, Says Analyst
CoronaNovavax: Street Underestimating Anticipated Strong Q2 and Outlook, Says Analyst
6M ago
NVAX
Is Moderna Stock a Buy Following Pediatric Covid-19 Vaccine Data? Analyst Weighs In
CoronaIs Moderna Stock a Buy Following Pediatric Covid-19 Vaccine Data? Analyst Weighs In
11M ago
PFE
BNTX
Novavax: Rising Cases Could Lead to Faster Uptake of Covid-19 Vaccine
CoronaNovavax: Rising Cases Could Lead to Faster Uptake of Covid-19 Vaccine
11M ago
NVAX
Novavax: Covid-19 Vaccine Has Good Odds for EUA Approval, Says Analyst
CoronaNovavax: Covid-19 Vaccine Has Good Odds for EUA Approval, Says Analyst
11M ago
NVAX
Vaxart Stock: Awaiting Platform Validation for the Bull-Case to Kick In
CoronaVaxart Stock: Awaiting Platform Validation for the Bull-Case to Kick In
11M ago
VXRT
In Search of a Better Covid Vaccine, This Analyst Taps Ocugen
CoronaIn Search of a Better Covid Vaccine, This Analyst Taps Ocugen
1y ago
Novavax Stock Could Hit $315, Says Analyst
CoronaNovavax Stock Could Hit $315, Says Analyst
1y ago
Is Gritstone Stock a Buy Right Now? This Is What You Need to Know
CoronaIs Gritstone Stock a Buy Right Now? This Is What You Need to Know
1y ago
Is 15% Potential Upside Good Enough to Risk Buying Inovio  Stock? Analyst Weighs In
CoronaIs 15% Potential Upside Good Enough to Risk Buying Inovio Stock? Analyst Weighs In
1y ago
Why This Analyst Sees Over 80% Upside Potential for Vaxart Stock
CoronaWhy This Analyst Sees Over 80% Upside Potential for Vaxart Stock
1y ago
VXRT
Moderna Stock Is Overvalued by 30%, Says JPMorgan
CoronaModerna Stock Is Overvalued by 30%, Says JPMorgan
1y ago
Novavax: Analysts Applaud the Latest Developments
CoronaNovavax: Analysts Applaud the Latest Developments
1y ago
Ocugen’s Covid-19 Vaccine Might Have One up on mRNA Vaccines
CoronaOcugen’s Covid-19 Vaccine Might Have One up on mRNA Vaccines
1y ago
Pfizer Vaccine Less Effective on Omicron in South Africa
CoronaPfizer Vaccine Less Effective on Omicron in South Africa
1y ago
NASDAQ
Moderna: Too Early to Tell Whether Flu Vaccine Has Differentiating Features
CoronaModerna: Too Early to Tell Whether Flu Vaccine Has Differentiating Features
1y ago
Moderna Accelerates COVID-19 Vaccine Supply to COVAX
CoronaModerna Accelerates COVID-19 Vaccine Supply to COVAX
1y ago
NASDAQ
Moderna Stock Dips Again; Valuation Remains Steep
CoronaModerna Stock Dips Again; Valuation Remains Steep
1y ago
NASDAQ
AstraZeneca Lands FDA Authorization; What Next?
CoronaAstraZeneca Lands FDA Authorization; What Next?
1y ago
NASDAQ
Moderna Takes a Hit Against Omicron
CoronaModerna Takes a Hit Against Omicron
1y ago
NASDAQ
Moderna to Supply Additional COVID-19 Vaccines to the UK
CoronaModerna to Supply Additional COVID-19 Vaccines to the UK
1y ago
NASDAQ
Novavax: Covid-19 Vaccine’s Rollout Could Play Part in Combating Omicron Variant
CoronaNovavax: Covid-19 Vaccine’s Rollout Could Play Part in Combating Omicron Variant
1y ago
Ocugen: IND Halt Not a Concern for Covaxin, Says Analyst
CoronaOcugen: IND Halt Not a Concern for Covaxin, Says Analyst
1y ago
Moderna: The Best Covid-19 Vaccine Maker Around, Says Analyst
CoronaModerna: The Best Covid-19 Vaccine Maker Around, Says Analyst
1y ago
Pfizer: Shares Are Overvalued but the Developing Covid Story Remains a Catalyst
CoronaPfizer: Shares Are Overvalued but the Developing Covid Story Remains a Catalyst
1y ago
NASDAQ
Novavax: Covid-19 Vaccine Gathering Momentum
CoronaNovavax: Covid-19 Vaccine Gathering Momentum
1y ago
Moderna: What You Need to Know Right Now
CoronaModerna: What You Need to Know Right Now
1y ago
Inovio Stock at $35 a Share? This Analyst Thinks It’s Possible
CoronaInovio Stock at $35 a Share? This Analyst Thinks It’s Possible
1y ago
Ocugen: What You Need to Know Right Now
CoronaOcugen: What You Need to Know Right Now
1y ago
Sorrento: Covid-19 Tests Could Generate Significant Revenue, Says Analyst
CoronaSorrento: Covid-19 Tests Could Generate Significant Revenue, Says Analyst
1y ago
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.